Genital Herpes

Topical Interferon Treatment Studied

Published in Hepatitis Weekly, September 11th, 2000

Viragen, Inc. (VRA), Plantation, Florida, announced that it has agreed to supply Omniferon to Zonagen, Inc. (ZONA) (ZNG) for the purpose of studying a topically applied enhanced formulation of natural alpha interferon for the treatment of genital herpes.

Zonagen has been awarded a Phase I Small Business Innovation Research Grant (SBIR) from the U.S. National Institutes of Health (NIH) to conduct studies using Omniferon in targeting genital herpes. Omniferon is produced in Edinburgh, Scotland, and is currently in Phase II clinical trials in Europe for hepatitis C.

Genital herpes is a sexually transmitted disease caused by the herpes simplex virus...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry